Risk of Brain Tumors in Children and Susceptibility to Organophosphorus Insecticides: The Potential Role of Paraoxonase (PON1) by Nielsen, Susan Searles et al.
Environmental Health Perspectives • VOLUME 113 | NUMBER 7 | July 2005 909
Some epidemiologic studies have observed
increased risk of childhood brain tumors
(CBTs) in relation to home pesticide use, farm
residence, or parental occupation in agriculture
(Bunin et al. 1994; Cordier et al. 2001; Davis
et al. 1993; Eﬁrd et al. 2003; Holly et al. 1998;
Kristensen et al. 1996; Pogoda and Preston-
Martin 1997). Organophosphorus insecticides
(OPs) target the nervous system, and it is pos-
sible that CBT occurrence is associated with
prenatal or childhood exposure to OPs or a
reduced ability to metabolize them. One impor-
tant OP-detoxifying enzyme is paraoxonase 1
(PON1). Present in the liver and blood, PON1
hydrolyzes the acetylcholinesterase-inhibiting
oxons (activated intermediates) of some OPs,
including chlorpyrifos and diazinon (Costa et al.
2002), which are important in agriculture and
in recent decades were the most common insec-
ticides used in homes and yards (Donaldson
et al. 2002). Although some environmental
exposures inﬂuence PON1 activity (Costa et al.
2005), they appear to have much less effect
than genetic variation (Jarvik et al. 2002); thus,
PON1 levels are relatively stable after they
reach adult levels at 6–15 months of age (Cole
et al. 2003).
The PON1 gene contains several common
single nucleotide polymorphisms, some of
which directly affect OP metabolism. In the
promoter region, adjacent to a binding site
for the transcription factor Sp1 (Deakin et al.
2003), the C-108T polymorphism inﬂuences
expression of the gene, with the PON1-108T
allele conferring reduced PON1 levels. It is
the most inﬂuential known polymorphism in
the promoter region, contributing 22–25%
of variation in PON1 expression in white
adults (Brophy et al. 2001; Leviev and James
2000). Relative to PON1-108CC homozygotes,
PON1-108TT homozygotes have, on average,
33–45% lower enzyme activity as adults
(Brophy et al. 2001; Leviev and James 2000)
and 63% lower as neonates (Chen et al. 2003).
PON1’s OP detoxification activity is also
inﬂuenced by enzyme structure, and a coding
region polymorphism, Q192R, determines
whether glutamine (Q) or arginine (R) is pre-
sent near PON1’s catalytic center (Harel et al.
2004). The two resulting PON1192 isoforms
hydrolyze some substrates at different rates. In
mice, PON1R192 isoform provides signifi-
cantly better protection than does PON1Q192
from chlorpyrifos oxon (Li et al. 2000). The
two isoforms provide similar protection with
respect to the oxon of diazinon.
Because chlorpyrifos and diazinon are
common in children’s environments (Andrew
Clayton et al. 2003) and PON1 genotype may
influence susceptibility to these OPs (Cole
et al. 2003), we examined whether the inefﬁ-
cient PON1 promoter allele (PON1-108T) or
the allele coding for the PON1192 isoform
that may provide lower chlorpyrifos protec-
tion (PON1192Q) are associated with increased
risk of CBT in children.
Materials and Methods
Subject identiﬁcation and specimen collection.
Institutional review board approvals were
received from the Fred Hutchinson Cancer
Research Center and Washington State
Department of Health (WDOH) before the
conduct of this study. Most subjects were
drawn from a previous case–control study
(Gurney et al. 1996), with additional control
subjects randomly selected from similar birth
years. Brieﬂy, in the previous study, cases were
diagnosed with primary tumors of the brain,
cranial nerves, or meninges [International
Classiﬁcation of Diseases for Oncology (ICD-O;
World Health Organization [WHO] 1976),
codes 191.0–192.1] at < 20 years of age in
1984–1991 while residing in the Seattle–
Puget Sound region of Washington State cov-
ered by a population-based cancer incidence
registry affiliated with the National Cancer
Institute’s Surveillance, Epidemiology, and
End Results Program. Controls from the same
counties were identified via random digit
dialing (RDD), frequency matched to cases
2:1 by sex and age. Mothers of all participat-
ing children [134 (74%) eligible cases and
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Prior research suggests that childhood brain tumors (CBTs) may be associated with exposure to
pesticides. Organophosphorus insecticides (OPs) target the developing nervous system, and until
recently, the most common residential insecticides were chlorpyrifos and diazinon, two OPs
metabolized in the body through the cytochrome P450/paraoxonase 1 (PON1) pathway. To
investigate whether two common PON1 polymorphisms, C-108T and Q192R, are associated with
CBT occurrence, we conducted a population-based study of 66 cases and 236 controls using DNA
from neonatal screening archive specimens in Washington State, linked to interview data. The risk
of CBT was nonsignificantly increased in relation to the inefficient PON1 promoter allele [per
PON1-108T allele, relative to PON1-108CC: odds ratio (OR) = 1.4; 95% conﬁdence interval (CI),
1.0–2.2; p-value for trend = 0.07]. Notably, this association was strongest and statistically signiﬁ-
cant among children whose mothers reported chemical treatment of the home for pests during
pregnancy or childhood (per PON1-108T allele: among exposed, OR = 2.6; 95% CI, 1.2–5.5;
among unexposed, OR = 0.9; 95% CI, 0.5–1.6) and for primitive neuroectodermal tumors (per
PON1-108T allele: OR = 2.4; 95% CI, 1.1–5.4). The Q192R polymorphism, which alters the struc-
ture of PON1 and inﬂuences enzyme activity in a substrate-dependent manner, was not associated
with CBT risk, nor was the PON1C-108T/Q192R haplotype. These results are consistent with an
inverse association between PON1 levels and CBT occurrence, perhaps because of PON1’s ability to
detoxify OPs common in children’s environments. Larger studies that measure plasma PON1 levels
and incorporate more accurate estimates of pesticide exposure will be required to confirm these
observations. Key words: brain tumor, children, chlorpyrifos, diazinon, dried blood spots, Guthrie
cards, paraoxonase, pesticides, PON1, xenobiotic metabolism. Environ Health Perspect 113:909–913
(2005). doi:10.1289/ehp.7680 available via http://dx.doi.org/ [Online 18 March 2005]
Research | Children’s Health281 (79%) eligible controls] were interviewed
using a structured questionnaire that included
questions about home pesticide treatment,
deﬁned as chemical treatment of the house for
pests such as termites, ﬂeas, ants, cockroaches,
or silverfish, during the index pregnancy
and/or childhood up to the diagnosis date
(cases) or similar reference date (controls).
A subset of these subjects [70 (52%) cases
and 160 (57%) controls] were eligible for the
present study because the child was born after
1977 and the mother resided in Washington
when the child was born, so a dried blood spot
(DBS) card potentially remained archived at
the WDOH Newborn Screening Program.
Blind to case status, staff located cards and
clipped a DBS for 66 (94%) eligible cases and
137 (86%) eligible controls. Most (74%) of
the unlocated subjects were born either in the
earliest, uncatalogued months (14 of 27) or
outside a civilian hospital (6 of 27). Case–
control, race/ethnicity, and histologic tumor
type proportions from the previous study were
preserved in the subset for whom DBS were
available. Subjects’ DBS were permanently
anonymized (American Society of Human
Genetics 1996) before removal from WDOH.
DBS from a pilot study that randomly sam-
pled 100 anonymous infants from the same
archives and a similar range of birth years
(1980–1991) were available to supplement
our control group.
DNA extraction and genotyping. DNA
extraction and genotyping were conducted at
the Center for Ecogenetics and Environmental
Health Functional Genomics Laboratory at the
University of Washington, blind to case status.
Six 3-mm punches were removed from each
DBS, with all instrumentation ﬂame sterilized
between specimens. DNA was then extracted
using the QIAamp DNA Mini Kit (QIAGEN,
Valencia, CA) according to the manufacturer’s
DBS protocol.
PON1 C-108T and Q192R variants were
identiﬁed with TaqMan detection system-based
assays (respective probes from Integrated DNA
Tehcnologies, Coralville, IA, and Applied
Biosystems, Foster City, CA). Genotypes were
assigned based on relative fluorescence, veri-
fied by sequencing as needed. Negative con-
trols and DNA-sequenced positive controls
representing each possible genotype were
included in each batch of analyses. We
included blind duplicate or quadruplicate
specimens for 6% of cases and 6% of inter-
viewed controls. All PON1 genotypes were
represented, and the results were in complete
agreement with the original specimens. In
addition, the laboratory repeated the assays for
> 10% randomly selected specimens, also in
full agreement.
PON1 genotyping was completed for all
subjects. One control for whom we collected
two equally well-matching DBS was excluded
from our CBT–PON1 analyses because PON1
genotype was different for the two possible
matches. Thus, 66 cases and 236 controls were
available for statistical analysis.
Statistical analysis. Genotype and allele
frequencies were tabulated, and chi-square tests
were used to check Hardy-Weinberg equilib-
rium. Using Intercooled Stata (version 8.0;
Stata Corp., College Station, TX), we con-
ducted logistic regression to estimate odds ratios
(ORs) and 95% conﬁdence intervals (CIs) for
CBT in relation to PON1 genotype (Breslow
and Day 1980). Because PON1 heterozygotes
have an intermediate phenotype (Brophy et al.
2001; Leviev and James 2000), each poly-
morphism was modeled linearly (0, 1, or 2
PON1-108T alleles; 0, 1, or 2 PON1192Q alleles).
To allow for possible threshold effects (e.g., any
vs. no PON1R192 isoform), the appropriateness
of the linear assumption was veriﬁed using the
likelihood-ratio test and by comparing modeled
risk estimates to those obtained for individual
genotypes. Test of trend p-values for CBT and
number of PON1-108T or PON1192Q alleles
were derived from the linear terms in the logis-
tic regression models.
To consider the possible combined effect
of the two polymorphisms, we investigated
whether risk estimates for one polymorphism
depended on the other and calculated CBT
risk estimates in relation to PON1C-108T/Q192R
diplotypes and haplotypes. For the latter,
we modeled the number of each allele (TQ,
TR, CQ, CR) linearly, using all subjects for
whom haplotype could be directly inferred or
accurately estimated (PHASE, version 2.0.2)
(Stephens et al. 2001). We also used PHASE
to test whether cases and controls had different
haplotype frequencies.
CBT (Gurney et al. 1999) and the PON1-
108T and PON1192Q alleles (Brophy et al.
2002; Chen et al. 2003) are more common in
non-Hispanic whites than in individuals of
most other races or ethnicities. To investigate
whether population stratification influenced
risk estimates, we repeated all analyses restricted
to children whose biologic mother and father
were both non-Hispanic white. Race/ethnicity
was not otherwise included in models because
there were few nonwhite or Hispanic subjects,
and within this heterogeneous category for
which prevalence of PON1 variants varies
widely, there were substantial racial/ethnic dif-
ferences between cases and controls.
Other potential confounders considered
were the other PON1 polymorphism (C-108T
by Q192R, and vice versa) and the frequency-
matching variables (sex and age). These were
retained in the models only if ORs or 95% CIs
for the PON1 polymorphisms were altered by
> 10%, and unless stated, unadjusted risk
estimates are presented. We also examined
whether CBT–PON1 risk estimates varied
by reported home pesticide treatment, farm
residence, or parental agricultural occupation,
potential indicators of exposure to OPs metab-
olized by PON1. Statistical interaction on the
multiplicative scale was assessed in logistic
regression models by the p-value (α = 0.05) of
the interaction term, or likelihood-ratio test
when a single interaction required multiple
terms. To the extent possible, we calculated
risk estimates by histologic subtype: astroglial
tumors (ICD-O histology codes 9380–9384,
9400–9421, 9424–9442), primitive neuroec-
todermal tumors (PNETs; 9362, 9470–9473,
9500), and other CBTs, using all controls as
the reference group (WHO 1976).
Results
Subject characteristics. Approximately half of
cases had astroglial tumors, with the remainder
evenly divided between PNETs and a hetero-
geneous group of other tumors (Table 1).
Most cases (71%) were diagnosed before the
age of 5 years. Similar proportions of cases
(88%) and controls (91%) were non-Hispanic
white; however, among subjects for whom
the father’s race/ethnicity was known (63 cases,
135 interviewed controls), proportionally fewer
cases (81%) than controls (93%) were born to
two non-Hispanic white parents.
Proportionally fewer mothers of cases
(31%) than controls (42%) reported that any
of the child’s homes had ever been chemically
treated for pests during the pregnancy or
childhood before the diagnosis/reference date.
In this largely urban/suburban region, few
subjects had ever lived on a farm (9% cases,
3% controls) or had parents who worked in
agriculture (14% cases, 10% controls).
PON1 genotype. PON1 genotype frequen-
cies did not significantly differ from Hardy-
Weinberg equilibrium (both p > 0.20).
Proportionally more cases (26%) than controls
(17%) were homozygous for the inefficient
PON1 promoter allele (PON1-108T), and risk
of CBT was nonsignificantly increased with
increasing PON1-108T alleles (for PON1-108TT,
relative to PON1-108CC: OR = 2.1; 95% CI,
0.9–4.7; for PON1-108CT, OR = 1.4; 95% CI,
1.0–2.2; p-value for trend = 0.07; Table 2).
The association was strongest and statistically
signiﬁcant in relation to the PNET histologic
tumor type specifically (for each additional
PON1-108T allele: OR = 2.4; 95% CI, 1.1–5.4;
p-value for trend = 0.03, based on 15 PNET
cases, including 6 PON1-108TT homozygotes
and 7 heterozygotes; data not shown).
According to PON1192 genotype, 48% cases
and 42% controls had no PON1R192 isoform
(Table 2). Although there was a weak sugges-
tion of increased CBT risk in relation to
increasing number of PON1192Q alleles, CIs
were quite wide and the p-value for trend was
nonsignificant (for PON1192QQ, relative to
PON1192RR: OR = 1.5; 95% CI, 0.6–3.4; for
PON1192QR: OR = 1.2; 95% CI, 0.8–1.9;
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p-value for trend = 0.36). None of the above
risk estimates was attenuated when we
restricted the analysis to children with two
non-Hispanic white parents, nor were they
markedly altered when we separately used
either the interviewed controls identified
through RDD or the anonymous WDOH
archive controls as the reference group.
Logistic regression models indicated no
interaction (p = 0.75) between these two
PON1 polymorphisms. Indeed, we observed a
positive association between CBT and the
PON1-108T allele within each PON192 geno-
type, and the estimated risk per PON1-108T
allele was nearly identical in children with
(OR = 1.5; 95% CI, 0.9–2.6) or without
(OR = 1.4; 95% CI, 0.8–2.5) any PON1R192
isoform (data not shown). However, with
respect to CBT–PON1Q192R, the possible weak
association was absent among PON1-108TT
homozygotes (per PON1192Q allele relative to
PON1192RR: OR = 1.0; 95% CI, 0.4–2.8.
PON1 diplotype and haplotype. We
observed proportionally more cases than con-
trols in each PON1C-108T/Q192R diplotype
with two inefﬁcient PON1 promoters and in
the CT/QQ diplotype (no PON1R192 iso-
form and only one efficient promoter allele;
data not shown). Proportionally fewer cases
were represented in each of the other diplo-
types, those with two efficient promoters or
those with only one efficient promoter but
some PON1R192 isoform.
PON1C-108T/Q192R haplotype frequencies
were not signiﬁcantly different in cases versus
controls (p = 0.09). The haplotype model con-
firmed the earlier impression that the
PON1192Q allele was not associated with CBT
among PON1-108TT homozygotes: the risk of
CBT relative to children with the CR/CR
haplotype (homozygous for efficient promo-
tion of PON1192R isoform) was 1.7 (95% CI,
1.0–3.2) per TQ allele, 1.7 (95% CI, 0.6–4.3)
per TR allele, and 1.3 (95% CI, 0.7–2.6) per
CQ allele. However, the resulting risk esti-
mates for individual diplotypes were not
markedly different from those estimated by
simpler models, including one with only a sin-
gle linear term for each polymorphism.
PON1 and pesticide exposure indicators.
CBT risk was associated with PON1C-108T
only among children whose mothers reported
that at least one of the child’s homes had
been chemically treated for pests. Relative to
PON1-108CC, the risk per PON1-108T allele
was 2.6 (95% CI, 1.2–5.5), whereas among
children whose homes were reportedly not
treated, the risk was 0.9 (95% CI, 0.5–1.6;
interaction p = 0.03; Table 3). Any suggestion
of an interaction between PON1Q192R and
home pesticide treatment was not statistically
signiﬁcant (p = 0.33; Table 4). These observa-
tions did not appear to be caused by case–
control differences in demographic factors
associated with pesticide use/reporting, such as
race/ethnicity, maternal education, or smok-
ing. Our ability to examine the CBT–PON1
relation by farm residence or parental agricul-
tural occupation was quite limited, although
there was a higher frequency of PON1-108TT
cases among children who had lived on a farm
(4 of 6 cases, 0 of 4 controls). Combining all
three pesticide exposure indicators, the risk of
CBT per PON1-108T allele was 2.0 (95% CI,
1.03–3.7) among exposed and 1.0 (95% CI,
0.5–1.9) among unexposed (interaction p =
0.15; data not shown.)
Discussion
This small population-based study suggests
that having an inefficient PON1 promoter
allele at position –108 is associated with an
increased risk of CBT. The observed associa-
tion was strongest with respect to PNET, the
CBT type most consistently associated with
farm residence (Bunin et al. 1994; Kristensen
et al. 1996). For the most part, CBT was not
associated with the PON1Q192R polymor-
phism, which determines the enzyme’s struc-
ture and thereby detoxiﬁcation efﬁciency for
some substrates. Our results were similar when
we focused on the largest racial/ethnic group
in our population, indicating that potential
biases related to race/ethnicity were probably
not largely responsible for our observations.
In addition, risk estimates were fairly resilient
to exclusion of either of the two population-
based sources of controls. Nevertheless, any
Child brain tumors and PON1 insecticide metabolism
Table 1. Demographic characteristics and selected exposures among children with and without brain
tumors [n (%)].
Interviewed Anonymous All
Cases controls controls controls
(n = 66) (n = 136) (n = 100) (n = 236)
Race/ethnicitya
White 58 (88) 131 (96) 33 (75) 164 (91)
Black 0 (0) 2 (1) 4 (9) 6 (3)
Hispanic 0 (0) 1 (1) 5 (11) 6 (3)
Asian 3 (5) 0 (0) 2 (5) 2 (1)
Other 5 (8) 2 (1) 0 (0) 2 (1)
Male 42 (64) 84 (62) 57 (58)b 141 (60)b
Birth year
1978–1983 30 (45) 71 (52) 50 (50) 121 (51)
1984–1991 36 (55) 65 (48) 50 (50) 115 (49)
Age at diagnosis/reference (years)
< 5 47 (71) 89 (65) — —
5–10 19 (29) 47 (35) — —
Mother smoked during pregnancy 10 (15) 23 (17) — —
Pesticide exposure indicators
Home pesticide treatmentc 20 (31)d 57 (42) — —
Farm residencec 6 (9) 4 (3) — —
Parental agricultural occupatione 9 (14) 14 (10) — —
Histologic tumor type
Astroglial 37 (56) — — —
PNET 15 (23) — — —
Other 14 (21) — — —
—, data not available.
aAs determined by maternal interview (cases and interviewed controls) or checkbox for child on DBS card (anonymous
controls; not available for births before 1990); percentage excludes 56 anonymous controls for whom race/ethnicity was
not reported. bPercentage excludes two anonymous controls for whom sex was not reported on the DBS card. cDuring
pregnancy or childhood before diagnosis/reference date. dPercentage excludes one case for whom pesticide use was
unknown. eIn year of birth or prior 4 years: agricultural occupation/industry (Cordier et al. 2001), or occupational exposure
to pesticides/weedkillers, fertilizer, “other” agricultural chemicals, farm animals, manure, or other potential indicators
of chlorpyrifos/diazinon contact (domestic animals/birds for resale, unprocessed wool, hides/skins/feathers, or “other”
animal products, excluding raw meat and milk).
Table 2. Risk of CBT in relation to PON1 C-108T and Q192R polymorphisms [n (%)].
All subjects Subjects with white parentsa
Cases Controls Cases Controls
PON1 genotype (n = 66) (n = 236) OR (95% CI)b (n = 51) (n = 125) OR (95% CI)b
C-108T: PON1 promotion
TT (inefﬁcient) 17 (26) 39 (17) 2.1 (0.9–4.7) 14 (27) 22 (18) 2.6 (1.0–6.9)
CT (intermediate) 34 (52) 125 (53) 1.4 (1.0–2.2) 28 (55) 66 (53) 1.6 (1.0–2.6)
CC (efﬁcient) 15 (23) 72 (31) 1.0 (reference) 9 (18) 37 (30) 1.0 (reference)
Q192R: PON1R192 isoform
QQ (none) 32 (48) 100 (42) 1.5 (0.6–3.4)c 27 (53) 58 (46) 1.6 (0.5–4.6)
QR (some) 28 (42) 105 (44) 1.2 (0.8–1.9)c 21 (41) 57 (46) 1.3 (0.7–2.1)
RR (all) 6 (9) 31 (13) 1.0 (reference) 3 (6) 10 (8) 1.0 (reference)
aBiologic mother and father both reportedly non-Hispanic and white; excludes 3 cases, 1 interviewed control, and
100 anonymous controls for whom father’s race/ethnicity unknown. bFor individual genotypes, with each polymorphism
modeled linearly (0, 1, or 2 PON1-108T alleles; 0, 1, or 2 PON1192Q alleles) using logistic regression. cAdjusted for PON1C-108T.association between CBT and PON1C-108T,
and the lack thereof between CBT and
PON1Q192R, must be interpreted with caution.
First, our small numbers of subjects
may have hampered our ability to observe a
CBT–PON1Q192R association and simultane-
ously increased the probability that the appar-
ent association between CBT and PON1C-108T
is a false positive. Furthermore, no prior studies
have examined this relationship. Non-Hodgkin
lymphoma (Kerridge et al. 2002), multiple
myeloma (Lincz et al. 2004), and prostate
cancer (Antognelli et al. 2004; Marchesani
et al. 2003) have been associated with other
PON1 polymorphisms, including Q192R,
but to our knowledge this is the first cancer
study to consider the C-108T polymorphism
of PON1, and the ﬁrst study to examine the
potential role of this enzyme in relation to
childhood cancer.
Second, we obtained subjects’ DNA from
an indirect source. It is possible that environ-
mental DNA contamination occurred, which
would likely bias risk estimates toward null.
However, our assays do not simply detect the
presence of an allele, but instead rely on rela-
tive amounts of each allele compared with
sequence-veriﬁed laboratory controls to assign
one of three genotypes.
Third, although our specimen retrieval rate
for cases was very high and did not require
cases to have survived, we cannot rule out
survival-related selection bias among cases in
the study from which they were drawn.
However, even if such bias existed and PON1
genotype influenced cancer prognosis, it is
unlikely this could account fully for the mod-
erately strong association we observed between
CBT and PON1C-108T.
To the extent that this association is not
due to chance or case survival, these results
suggest that CBT risk may be inversely related
to PON1 enzyme levels. Ideally, fresh blood
would have been available and PON1 enzyme
levels measured, but the C-108T polymor-
phism is a significant determinant of PON1
levels in both neonates and pregnant women
(Chen et al. 2003). Because PON1 may
hydrolyze OPs before they can reach the brain,
our results lend support to prior epidemiologic
studies that have observed an increased risk of
CBT in relation to possible pesticide exposure.
OPs target the developing nervous system
(Garcia et al. 2002; Johnson et al. 1998), and
chlorpyrifos may affect replication and dif-
ferentiation of glial cells (Garcia et al. 2001).
If OPs do relate to CBT risk, one would
expect CBT–PON1 associations to be present
mainly among those exposed to chlorpyrifos
and/or diazinon. These two OPs were the
most common residential insecticides during
the study years, and indoor air is an important
source of children’s exposure to them (Andrew
Clayton et al. 2003). Therefore, it is interest-
ing that we observed an increased risk of CBT
in relation to the inefﬁcient PON1-108T allele
only among children whose homes were
reportedly treated for insect pests. Still, one
cannot discount the possibility that this OP-
metabolizing enzyme could protect the brain
via its more generic ability to metabolize oxi-
dized lipid molecules. That PON1Q192R was
not associated with CBT seems to underscore
this point. However, the relative protection
provided by the two resulting PON1192 iso-
forms depends on the OP (Li et al. 2000),
and perhaps other factors such as PON1 lev-
els. We had no direct measures of these, nor
of the level of exposure to chlorpyrifos and
diazinon. Because of our modest number of
cases, we also had limited ability to consider
other potentially relevant factors, such as diet,
age at diagnosis, family history of cancer, and
prenatal and childhood exposure to tobacco
smoke. For example, there was some indica-
tion that the PON1192Q allele is associated
with increased risk of CBT among subjects
reportedly not exposed to tobacco smoke, but
we could not adequately examine whether
this reflects a plausible biologic effect or is
simply a spurious observation due to chance
or bias related to racial/ethnic differences
between cases and controls and smokers and
nonsmokers.
The strengths of our study are population-
based identiﬁcation of cases and controls, the
use of a DNA source unrelated to case sur-
vival, and inclusion of children diagnosed
before the residential phase-out of chlorpyrifos
and diazinon began. Future studies of CBT
and PON1 would beneﬁt from larger sample
sizes, more accurate indicators of exposure to
chlorpyrifos and diazinon, the addition of
other PON polymorphisms, measurement of
plasma PON1 activity (e.g., PON1 status)
(Costa and Furlong 2002), and genotyping/
phenotyping of both children and mothers. It
would also be useful to know whether the
PON1C-108T polymorphism is associated with
biomarkers of relevance to cancer, such as
chromosome aberrations, as has been demon-
strated in farmers with respect to PON1Q192R
(Au et al. 1999). Such studies would be worth-
while in light of the possible association we
observed between CBT occurrence and the
predominant polymorphism in the PON1 pro-
moter region, and because chlorpyrifos remains
a leading agricultural insecticide and is detected
in or on foods frequently consumed by chil-
dren (Andrew Clayton et al. 2003; U.S.
Department of Agriculture 2004).
REFERENCES
American Society of Human Genetics. 1996. ASHG report.
Statement on informed consent for genetic research. Am
J Hum Genet 59:471–474.
Andrew Clayton C, Pellizzari ED, Whitmore RW, Quackenboss
JJ, Adgate J, Sefton K. 2003. Distributions, associations,
and partial aggregate exposure of pesticides and poly-
nuclear aromatic hydrocarbons in the Minnesota Children’s
Pesticide Exposure Study (MNCPES). J Expo Anal Environ
Epidemiol 13:100–111.
Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. 2004.
Association of CYP17, GSTP1, and PON1 polymorphisms with
the risk of prostate cancer. Prostate 63:240–251. doi:10/1002/
pros.20184 [Online 10 November 2004].
Searles Nielsen et al.
912 VOLUME 113 | NUMBER 7 | July 2005 • Environmental Health Perspectives
Table 3. Risk of CBT in relation to PON1C-108T genotype, by ever/never chemical treatment of home for
insect pests during pregnancy or childhood.
Home pesticide PON1C-108T Cases Controls
treatmenta genotype [n = 65b (%c)] [n = 136d (%c)] OR (95% CI)e OR (95% CI)f
Yes TT 9 (45) 10 (18) 1.4 (0.5–3.9) 6.6 (1.5–29.7)
CT 8 (40) 26 (46) 0.5 (0.2–1.3) 2.6 (1.2–5.5)
CC 3 (15) 21 (37) 0.2 (0.1–0.7) 1.0 (reference)
No TT 7 (16) 13 (16) 0.8 (0.3–2.7)
CT 26 (58) 47 (59) 0.9 (0.5–1.6)
CC 12 (27) 19 (24) 1.0 (reference)
aBased on maternal interview; chemical treatment of home for termites, ﬂeas, cockroaches, ants, silverﬁsh, or other, during
index pregnancy or during childhood before diagnosis/reference date. bExcludes one case for whom home pesticide treat-
ment was unknown. cWithin respective pesticide category. dExcludes anonymous controls, due to absence of pesticide
interview data. eRelative to PON1-108CC homozygotes whose homes were not chemically treated for insect pests. fRelative to
PON1-108CC homozygotes whose homes were chemically treated for insect pests.
Table 4. Risk of CBT in relation to PON1Q192R genotype, by ever/never chemical treatment of home for
insect pests during pregnancy or childhood.
Home pesticide PON1Q192R Cases Controls
treatmenta genotype [n = 65b (%c)] [n = 136d (%c)] OR (95% CI)e OR (95% CI)f
Yes QQ 8 (40) 26 (46) 0.8 (0.2–2.4) 0.6 (0.1–3.3)
QR 10 (50) 27 (47) 1.0 (0.3–2.7) 0.8 (0.4–1.8)
RR 2 (10) 4 (7) 1.2 (0.3–5.2) 1.0 (reference)
No QQ 23 (51) 33 (42) 1.7 (0.6–5.4)
QR 18 (40) 37 (47) 1.3 (0.7–2.3)
RR 4 (9) 9 (11) 1.0 (reference)
aBased on maternal interview; chemical treatment of home for termites, ﬂeas, cockroaches, ants, silverﬁsh, or other, during
index pregnancy or during childhood before diagnosis/reference date. bExcludes one case for whom home pesticide treat-
ment was unknown. cWithin respective pesticide category. dExcludes anonymous controls, due to absence of pesticide
interview data. eRelative to PON1192RR homozygotes whose homes were not chemically treated for insect pests. fRelative to
PON1192RR homozygotes whose homes were chemically treated for insect pests.Child brain tumors and PON1 insecticide metabolism
Environmental Health Perspectives • VOLUME 113 | NUMBER 7 | July 2005 913
Au WW, Sierra-Torres CH, Cajas-Salazar N, Shipp BK, Legator
MS. 1999. Cytogenetic effects from exposure to mixed
pesticides and the influence from genetic susceptibility.
Environ Health Perspect 107:501–505.
Breslow NE, Day NE, eds. 1980. Statistical Methods in Cancer
Research: Vol I. The Analysis of Case-Control Studies. Lyon,
France:IARC Press.
Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik
GP, Furlong CE. 2001. Effects of 5’ regulatory-region poly-
morphisms on paraoxonase-gene (PON1) expression. Am
J Hum Genet 68:1428–1436.
Brophy VH, Jarvik GP, Furlong CE. 2002. PON1 Polymorphisms.
In: Paraoxonase (PON1) in Health and Disease: Basic and
Clinical Aspects (Costa LG, Furlong CE, eds). Boston:Kluwer
Academic Publishers, 53–77.
Bunin GR, Buckley JD, Boesel CP, Rorke LB, Meadows AT. 1994.
Risk factors for astrocytic glioma and primitive neuro-
ectodermal tumor of the brain in young children: a report
from the Children’s Cancer Group. Cancer Epidemiol
Biomarkers Prev 3:197–204.
Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. 2003.
Increased inﬂuence of genetic variation on PON1 activity
in neonates. Environ Health Perspect 111:1403–1409.
Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM,
et al. 2003. Expression of human paraoxonase (PON1) dur-
ing development. Pharmacogenetics 13:357–364.
Cordier S, Mandereau L, Preston-Martin S, Little J, Lubin F,
Mueller B, et al. 2001. Parental occupations and childhood
brain tumors: results of an international case-control study.
Cancer Causes Control 12:865–874.
Costa LG, Furlong CE. 2002. Perspectives in PON1 Research. In:
Paraoxonase (PON1) in Health and Disease: Basic and
Clinical Aspects (Costa L, Furlong CE, eds). Boston:Kluwer
Academic Publishers, 197–210.
Costa LG, Li WF, Richter RJ, Shih DM, Lusis AJ, Furlong CE. 2002.
PON1 and Organophosphate Toxicity. In: Paraoxonase
(PON1) in Health and Disease: Basic and Clinical Aspects
(Costa L, Furlong CE, eds). Boston:Kluwer Academic
Publishers, 165–183.
Costa LG, Vitalone A, Cole TB, Furlong CE. 2005. Modulation
of paraoxonase (PON1) activity. Biochem Pharmacol
69:541–550.
Davis JR, Brownson RC, Garcia R, Bentz BJ, Turner A. 1993.
Family pesticide use and childhood brain cancer. Arch
Environ Contam Toxicol 24:87–92.
Deakin S, Leviev I, Brulhart-Meynet MC, James RW. 2003.
Paraoxonase-1 promoter haplotypes and serum paraox-
onase: a predominant role for polymorphic position -107,
implicating the Sp1 transcription factor. Biochem J
372:643–649.
Donaldson D, Kiely T, Grube A. 2002. 1998/1999 Pesticide Sales
and Usage Report. Washington, DC:U.S. Environmental
Protection Agency.
Efird JT, Holly EA, Preston-Martin S, Mueller BA, Lubin F,
Filippini G, et al. 2003. Farm-related exposures and child-
hood brain tumours in seven countries: results from the
SEARCH International Brain Tumour Study. Paediatr Perinat
Epidemiol 17:201–211.
Garcia SJ, Seidler FJ, Crumpton TL, Slotkin TA. 2001. Does the
developmental neurotoxicity of chlorpyrifos involve glial
targets? Macromolecule synthesis, adenylyl cyclase sig-
naling, nuclear transcription factors, and formation of
reactive oxygen in C6 glioma cells. Brain Res 891:54–68.
Garcia SJ, Seidler FJ, Qiao D, Slotkin TA. 2002. Chlorpyrifos tar-
gets developing glia: effects on glial fibrillary acidic pro-
tein. Brain Res Dev Brain Res 133:151–161.
Gurney J, Smith M, Bunin G. 1999. CNS and miscellaneous
intracranial and intraspinal neoplasms. In: Cancer Incidence
and Survival among Children and Adolescents: United States
SEER Program 1975–1995 (Ries LAG, Smith MA, Gurney JG,
Linet M, Tamra T, Young JL, et al., eds). NIH Pub. No. 99-
4649. Bethesda, MD:National Institutes of Health, 51–63.
Gurney JG, Mueller BA, Davis S, Schwartz SM, Stevens RG,
Kopecky KJ. 1996. Childhood brain tumor occurrence in
relation to residential power line configurations, electric
heating sources, and electric appliance use. Am J Epidemiol
143:120–128.
Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O,
Meged R, et al. 2004. Structure and evolution of the serum
paraoxonase family of detoxifying and anti-atherosclerotic
enzymes. Nat Struct Mol Biol 11:412–419.
Holly EA, Bracci PM, Mueller BA, Preston-Martin S. 1998. Farm
and animal exposures and pediatric brain tumors: results
from the United States West Coast Childhood Brain Tumor
Study. Cancer Epidemiol Biomarkers Prev 7:797–802.
Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter
RJ, et al. 2002. Vitamin C and E intake is associated with
increased paraoxonase activity. Arterioscler Thromb Vasc
Biol 22:1329–1333.
Johnson DE, Seidler FJ, Slotkin TA. 1998. Early biochemical
detection of delayed neurotoxicity resulting from develop-
mental exposure to chloropyrifos. Brain Res Bull 45:143–147.
Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A.
2002. Association between xenobiotic gene polymor-
phisms and non-Hodgkin’s lymphoma risk. Br J Haematol
118:477–481.
Kristensen P, Andersen A, Irgens LM, Bye AS, Sundheim L.
1996. Cancer in offspring of parents engaged in agricultural
activities in Norway: incidence and risk factors in the farm
environment. Int J Cancer 65:39–50.
Leviev I, James RW. 2000. Promoter polymorphisms of human
paraoxonase PON1 gene and serum paraoxonase activi-
ties and concentrations. Arterioscler Thromb Vasc Biol
20:516–521.
Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et al.
2000. Catalytic efficiency determines the in-vivo efficacy
of PON1 for detoxifying organophosphorus compounds.
Pharmacogenetics 10:767–779.
Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A, Spencer A.
2004. Xenobiotic gene polymorphisms and susceptibility to
multiple myeloma. Haematologica 89:628–629.
Marchesani M, Hakkarainen A, Tuomainen TP, Kaikkonen J,
Pukkala E, Uimari P, et al. 2003. New paraoxonase 1 poly-
morphism I102V and the risk of prostate cancer in Finnish
men. J Natl Cancer Inst 95:812–818.
Pogoda JM, Preston-Martin S. 1997. Household pesticides and
risk of pediatric brain tumors. Environ Health Perspect
105:1214–1220.
Stephens M, Smith NJ, Donnelly P. 2001. A new statistical
method for haplotype reconstruction from population data.
Am J Hum Genet 68:978–989.
U.S. Department of Agriculture. 2004. Pesticide Data Program:
Annual Summary Calendar Year 2002. Washington, DC:U.S.
Department of Agriculture, Agricultural Marketing Service.
WHO. 1976. International Classification of Diseases for
Oncology. 1st ed. Geneva:World Health Organization.